Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021

• DOI: 10.15585/mmwr.mm7102e1
• Publication Date: 2022-01-07T09:28:17Z
• Authors: Laura D. Zambrano; Margaret M. Newhams; Samantha M. Olson; Natasha B. Halasa; Ashley M. Price; Julie A. Boom; Leila C. Sahni; Satoshi Kamidani; Keiko M. Tarquinio; Aline B. Maddux; Sabrina M. Heidemann; Samina S. Bhumbra; Katherine E. Bline; Ryan A. Nofziger; Charlotte V. Hobbs; Tamara T. Bradford; Natalie Z. Cvijan...; Katherine Irby; Elizabeth H. Mack; Melissa L. Cullimore; Pia S. Pannaraj; Michele Kong; Tracie C. Walker; Shira J. Gertz; Kelly N. Michelson; Melissa A. Cameron; Kathleen Chiotos; Mia Maamari; Jennifer E. Schuster; Amber O. Orzel; Manish M. Patel; Angela P. Campbell; Adrienne G. Randolph; ; ; Meghan Murdock; Mary Glas Gaspers; Katri V. Typpo; Connor P. Kelley; Ronald C. Sanders; Masson Yates; Chelsea Smith; Katheryn Crane; Geraldina Lionetti; Juliana Murcia-Mo...; Matt S. Zinter; Denise Villarreal...; Adam L. Skura; Harvey Peralta; Justin M. Lockwood; Emily Port; Imogene A. Carson; Brandon M. Chatani; Laila Hussaini; Nadine Baida; Bria M. Coates; Courtney M. Rowan; Mary Stumpf; Marla S. Johnston; Benjamin J. Bouts...; Suden Kucukak; Sabrina R. Chen; Edie Weller; Laura Berbert; Jie He; Heidi R. Flori; Janet R. Hume; Ellen R. Bruno; Lexie A. Goertzen; Emily R. Levy; Supriya Behl; Noelle M. Drapeau; Lora Martin; Lacy Malloch; Cameron Sanders; Kayla Patterson; Anita Dhanrajani; Shannon M. Hill; Abigail Kietzman; Valerie H. Rinehart; Lauren A. Hoody; Stephanie P. Schw...; Angelo G. Navas; Paris C. Bennett; Nicole A. Twinem; Merry L. Tomcany; Mary Allen Staat; Chelsea C. Rohlfs; Amber Wolfe; Rebecca L. Douglas; Kathlyn Phengchom...; Megan M. Bickford; Lauren E. Wakefield; Laura Smallcomb; Laura S. Stewart; Meena Golchha; Jennifer N. Oates; Cindy Bowens
• Keywords: Regimen

Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In United States, BNT162b2 (Pfizer-BioNTech) vaccine currently authorized for use and adolescents aged 5-15 years under an Emergency Use Authorization fully licensed by Food Drug Administration persons ≥16 (4). Prelicensure randomized trials ≥5 documented high efficacy immunogenicity (5),§ real-world studies 12-18 demonstrated effectiveness (VE) against (6). Recent evidence suggests vaccination associated lower MIS-C incidence among (7); however, VE of 2-dose Pfizer-BioNTech regimen has not been evaluated. The 2 doses received ≥28 days before hospital admission preventing was assessed using test-negative case-control design¶ hospitalized patients at 24 pediatric hospitals 20 states** during July 1-December 9, 2021, period when most could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance. Patients (case-patients) two groups controls matched case-patients were evaluated: had least one COVID-19-like symptom negative reverse transcription-polymerase chain reaction (RT-PCR) antigen-based assay results, syndrome-negative without illness. Among 102 181 controls, estimated 91% (95% CI = 78%-97%). All 38 requiring life support unvaccinated. Receipt level protection years, highlighting importance all eligible children.